Ribosomal therapy in the prophylaxis of recurrent pharyngotonsillitis in children

Mora, Renzo; Dellepiane, Massimo; Crippa, Barbara; Salami, Angelo

doi:10.1016/j.ijporl.2006.10.007

Cited by 11 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 ) [ 44 ]. Furthermore, oral administration causes expansion of constituent-specific B cells and sIgA production [ 45 , 46 , 61 ], and increased serum IgA and IgG in children with RRTI [ 44 , 47 , 48 ]. Increased sIgA concentrations in healthy volunteers were associated with reduced adhesion of a constituent strain, Streptococcus pneumoniae (Table 1 ; Fig.…”

Section: Mechanism Of Action For Immunomodulators In Respiratory Tracmentioning

confidence: 99%

“…In a number of trials on children with RRTI, including those with adenoiditis, pharyngotonsillitis and otitis media, ribomunyl reduced the incidence, prevalence and/or duration of infections [ 44 , 47 , 48 , 78 , 79 ]. The use of antibiotics/ancillary therapy [ 44 , 47 , 48 , 79 ], school absenteeism [ 44 , 47 , 79 ] and medical visits [ 48 ] was also reduced. In a comparison of ribomunyl prophylaxis for patients with more or less than five RTIs in the past year, only those with five or less showed a decrease in incidence of infection, and physicians did not rate a significant improvement in either group.…”

Section: Efficacy Of Immunomodulators In Children With Respiratory Trmentioning

confidence: 99%

See 1 more Smart Citation

Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence

Esposito

Soto-Martinez

Feleszko

et al. 2018

Current Opinion in Allergy &Amp; Clinical Immunology

107

145

View full text Add to dashboard Cite

Purpose of reviewTo provide an overview of the mechanistic and clinical evidence for the use of nonspecific immunomodulators in paediatric respiratory tract infection (RTI) and wheezing/asthma prophylaxis.Recent findingsNonspecific immunomodulators have a long history of empirical use for the prevention of RTIs in vulnerable populations, such as children. The past decade has seen an increase in both the number and quality of studies providing mechanistic and clinical evidence for the prophylactic potential of nonspecific immunomodulators against both respiratory infections and wheezing/asthma in the paediatric population. Orally administered immunomodulators result in the mounting of innate and adaptive immune responses to infection in the respiratory mucosa and anti-inflammatory effects in proinflammatory environments. Clinical data reflect these mechanistic effects in reductions in the recurrence of respiratory infections and wheezing events in high-risk paediatric populations. A new generation of clinical studies is currently underway with the power to position the nonspecific bacterial lysate immunomodulator OM-85 as a potential antiasthma prophylactic.SummaryAn established mechanistic and clinical role for prophylaxis against paediatric respiratory infections by nonspecific immunomodulators exists. Clinical trials underway promise to provide high-quality data to establish whether a similar role exists in wheezing/asthma prevention.

show abstract

Section: Mechanism Of Action For Immunomodulators In Respiratory Tracmentioning

confidence: 99%

Section: Efficacy Of Immunomodulators In Children With Respiratory Trmentioning

confidence: 99%

Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence

Esposito

Soto-Martinez

Feleszko

et al. 2018

Current Opinion in Allergy &Amp; Clinical Immunology

107

145

View full text Add to dashboard Cite

show abstract

“…8 Another study reported on 172 children with either upper or lower respiratory tract infections, 86 randomized to RCIM. 8 Other published studies enrolled 160 children with recurrent pharyngotonsillitis, 20 155 children with otitis, 8 154 with upper airway respiratory infections, 8,21,22 and 136 with ear-nose-throat infections, 8,19,22,23 respectively. Only one of these studies was published in an English peer-review journal, 20 and all the others were only included in subsequent metaanalyses.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of ribosome-component immune modulator for preventing recurrent respiratory infections in socialized children

Fiocchi¹,

Omboni²,

Mora³

et al. 2012

allergy asthma proc

Self Cite

View full text Add to dashboard Cite

Attending day care is associated with recurrent respiratory infections (RRIs) and asthma. Ribosomal immunotherapy may confer protection against RRIs in children. This study was designed to assess the efficacy of a ribosome-component immune modulator (RCIM) as preventive treatment of respiratory infections in socialized children aged ≤5 years, with or without a history of frequent RRI. In a multicenter, Italian, randomized, double-blind, placebo-controlled, parallel-group study, 164 socialized day care center children (mean age, 3.8 ± 1.1 years) were treated with RCIM or placebo for 6 months and followed-up for additional 6 months. Outcomes are presented for the intent-to-treat population. In socialized children with five or less RRIs (n = 95; 49 RCIM and 46 placebo, group A) the duration of the infectious episodes was significantly shorter with RCIM than with placebo (6 months, 3.7 ± 2.1 versus 4.5 ± 1.9 days, p = 0.040; 12 months, 3.6 ± 2.0 versus 4.7 ± 2.5 days, p = 0.015). The proportion of patients reporting no respiratory infectious episodes with RCIM at 6 and 12 months was also significantly larger in group A (20.4% versus 4.4% placebo; p = 0.028). No such differences were found in children with more than five RRIs in the preceding year (n = 63; 32 RCIM and 31 placebo, group B). In all children, general well-being improved significantly more under RCIM than under placebo (11.6 ± 1.8% versus 10.2 ± 1.8%; p = 0.002). No statistically significant between-treatment differences were observed for other end points. Both treatments were similarly well tolerated. Six-month treatment with RCIM effectively prevented the 12-month risk of RRIs in children <5 years old and with five or less RRIs in the preceding year.

show abstract

“…At present, children affected by RURT infections are cured by means of antibacterial and symptomatic therapy. Especially in the paediatric age, antibacterial therapy is still the traditional approach [4].…”

Section: Introductionmentioning

confidence: 99%

Sulphurous water inhalations in the prophylaxis of recurrent upper respiratory tract infections

Salami

Dellepiane

Crippa

et al. 2008

International Journal of Pediatric Otorhinolaryngology

Self Cite

View full text Add to dashboard Cite

Ribosomal therapy in the prophylaxis of recurrent pharyngotonsillitis in children

Cited by 11 publications

References 16 publications

Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence

Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence

Efficacy and safety of ribosome-component immune modulator for preventing recurrent respiratory infections in socialized children

Sulphurous water inhalations in the prophylaxis of recurrent upper respiratory tract infections

Contact Info

Product

Resources

About